Hepatica
Hepatica
肝叶是一种传统植物，其具体的医疗用途尚未得到充分记录。它被研究以探索其潜在的好处，特别是用于治疗肝脏疾病如肝硬化。一项对照试验表明，在人类中TCBZ在10 mg/kg剂量下的治疗效果为92.31%；然而，对羊的小规模研究结果表明可能由于抗性而导致治疗失败，这表明了结果的变异性。在马身上发现胃肠道寄生虫的高流行率（88.80%），并鉴定出了十五种物种，但没有直接联系到肝叶的使用。药师主导的干预措施减少了48%患有肝硬化的患者的非计划住院次数，尽管所有原因死亡率并无显著差异。未记录任何重大安全问题或药物相互作用与肝叶有关。
- 最佳证据
- B
- 注意事项
- —
仅供参考。传统用法并不代表已被证实有效。证据与安全性各不相同，请查阅所引来源。
科学怎么说
- 患有肝硬化的患者中有一大部分接受了可能不适当的药物，其中一半的药剂师建议被接受。
- TCBZ 在每公斤 10 毫克的剂量下，对人类显示出92.31% 的治疗效果，而一项在绵羊中的对照试验表明由于可能存在的抗性而导致潜在的治疗失败。
- 在科特迪瓦阿比让地区的马匹中，胃肠道寄生虫的总体感染率为88.80%，共鉴定出15种。
- 研究发现，由药师领导的干预措施将肝硬化患者的非计划住院率降低了48%，尽管在所有原因死亡率方面未观察到显著差异。
Frequently asked questions
What is Hepatica?
Hepatica (Hepatica) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Hepatica?
4 sourced findings are recorded for Hepatica; the strongest carries evidence grade B. For example: 患有肝硬化的患者中有一大部分接受了可能不适当的药物，其中一半的药剂师建议被接受。
How strong is the evidence for Hepatica?
The strongest finding for Hepatica carries evidence grade B — moderate evidence. Grades run A (strongest) to D (preliminary or traditional).
Is Hepatica safe? What are the side effects?
No major safety issues are recorded for Hepatica in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Hepatica interact with medications?
No drug interactions are recorded for Hepatica in our sources. This does not rule them out — check with a pharmacist.
What are the common names of Hepatica?
Hepatica is also known as: печёночница.
Is Hepatica a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
来源
- T2 Efficacy of two triclabendazole regimens for treating human chronic fasciolosis and a controlled efficacy trial in sheep using human-isolate metacercariae in Cajamarca, Peru. literature abstract metadata
- T2 Evidence on the impact of treatment optimization on the safety of patients with liver cirrhosis. literature abstract metadata
- T2 Pharmaceutical intervention for the reduction of risks associated with medications in patients with liver cirrhosis in primary care. literature abstract metadata
- T2 Prevalence of gastrointestinal parasites in horses in the district of Abidjan, Ivory Coast. literature abstract metadata